化积胶囊抗肝纤维化的临床研究

The Clinical Study of Huaji Capsule on Resisting Hepatic Fibrosis

目的评价中药化积胶囊抗肝纤维化临床疗效。方法 120例早期乙肝肝硬化患者随机分为2组:中药化积胶囊治疗组60例,大黄蛰虫胶囊对照组60例,治疗6个月。观察治疗前后两组患者的症状、体征、肝功能、血清肝纤维化指标及肝脾影像学变化。结果治疗组总有效率为93.34%,对照组总有效率为80.01%,两组比较具有显著性差异(P<0.01)。结论化积胶囊可明显改善早期乙肝肝硬化患者的症状、体征、肝功能、血清肝纤维化4项指标(HA、LN、PCIII及IV-C)、及肝脾影像学表现,具有明显抗肝纤维化疗效。

Objective To evaluate the clinical curative effect caused by Huaji capsule in terms of anti-hepatofibrosis.Method one hundred twenty patients with fore-hepatocirrhosis due to chronic hepatitis B were divided into two groups at random.： treatment （Huaji capsule ） group was 60 cases,control （Dahuan Zhechong capsule ） group was 60 cases.After 6 months treatment,to observe the change of clinical symptoms,signs,hepatic function,hepatofibrosis indexes in serum,and B-ultrasonography of liver and spleen.Results The results showed that the total effective rate was 93.34% in the treatment group,80.01% in the control group,and there was significant difference between two groups （P0.01）.Conclusions Huaji capsule can evidently improve the clinical symptoms,signs,hepatic function,hepatofibrosis indexes （HA、LN、PC III、and IV-C ） and B-ultrasonography of liver and spleen of the patients with fore-hepatocirrhosis due to chronic hepatitis B,indicating that it has evident curative effect in terms of anti-hepatofibrosis.